CD274 and cancer: Discovery of immune checkpoints and the inhibitory activity of several members of them in lymphocytes [62, 63] initiated a plethora of studies in various cancers, which revealed that the PDL1 ligand (CD274) of the PD1 receptor is expressed by cancers and can be one of the main escape routes of immune destruction [64, 65].